PET Imaging Based Evaluation of Hepatobiliary Transport in Humans with (15R)-11C-TIC-Me

被引:86
作者
Takashima, Tadayuki [1 ,2 ]
Kitamura, Satoshi [3 ]
Wada, Yasuhiro [2 ]
Tanaka, Masaaki [2 ]
Shigihara, Yoshihito [2 ]
Ishii, Hideki [2 ]
Ijuin, Ryosuke [2 ]
Shiomi, Susumu [2 ]
Nakae, Takahiro
Watanabe, Yumiko
Cui, Yilong
Doi, Hisashi
Suzuki, Masaaki
Maeda, Kazuya [3 ]
Kusuhara, Hiroyuki [3 ]
Sugiyama, Yuichi [3 ]
Watanabe, Yasuyoshi [2 ]
机构
[1] RIKEN, Ctr Mol Imaging Sci, Mol Probe Dynam Lab, Chuo Ku, Kobe, Hyogo 6500047, Japan
[2] Osaka City Univ, Grad Sch Med, Abeno Ku, Osaka 558, Japan
[3] Univ Tokyo, Grad Sch Pharmaceut Sci, Lab Mol Pharmacokinet, Bunkyo Ku, Tokyo, Japan
关键词
PET; hepatobiliary transport; organic anion-transporting polypeptide; (15R)-16-m-tolyl-17; 18; 19; 20-tetranorisocarbacyclin methyl ester; drug-drug interaction; DRUG-DRUG INTERACTION; POSITRON-EMISSION-TOMOGRAPHY; GENETIC POLYMORPHISMS; IN-VITRO; RECEPTOR; OATP1B1; PHARMACOKINETICS; PITAVASTATIN; HEPATOCYTES; DETERMINANT;
D O I
10.2967/jnumed.111.098681
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
It is well accepted that drug transporters play a pivotal role in hepatobiliary excretion of anionic drugs, in which drug-drug interactions and genetic polymorphisms are known to cause variations. However, PET probes for in vivo functional characterization of these transporters have not been established yet. We used PET to investigate hepatic uptake and subsequent canalicular efflux of C-11-labeled (15R)-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin methyl ester [(15R)-C-11-TIC-Me)] in healthy subjects. Methods: Serial PET scans of the abdominal region in healthy male subjects were obtained with or without the organic anion-transporting polypeptide (OATP) inhibitor rifampicin after intravenous injection of (15R)-C-11-TIC-Me as a radiotracer. Venous blood samples and PET images were obtained at frequent intervals up to 30 min after administration of the PET tracer. Dynamic imaging data were evaluated by integration plots of data collected for 2-10 min and for 10-30 min after tracer administration for the determination of tissue uptake clearance and biliary efflux clearance, respectively. Results: After rapid hydrolysis in blood, the acid form-C-11-labeled (15R)-16-m-tolyl-17,18,19,20-tetranorisocarbacyclin [(15R)-C-11-TIC]-accumulated in the liver (37% of the dose by 17 min), and the radioactivity was then excreted into the bile (6.2% by 30 min). Rifampicin (600 mg by mouth), a potent OATP inhibitor, significantly reduced the radioactivity excreted into the bile (by 44%) by inhibiting both uptake (by 45%) and subsequent canalicular efflux (by 62%). (15R)-C-11-TIC is an in vitro substrate of OATP1B1 and OATP1B3, and clinically relevant concentrations of rifampicin inhibited uptake by OATP1B1 and OATP1B3. These results demonstrated that in humans, (15R)-C-11-TIC-associated radioactivity is excreted into the bile by organic anion transport systems. Conclusion: We demonstrated that PET image analysis with (15R)-C-11-TIC-Me is useful for investigating variations in OATP function in the human hepatobiliary transport system.
引用
收藏
页码:741 / 748
页数:8
相关论文
共 31 条
[1]   Positron emission tomography microdosing:: a new concept with application in tracer and early clinical drug development [J].
Bergström, M ;
Grahnén, A ;
Långström, B .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 59 (5-6) :357-366
[2]   Synthesis of 11C/13C-labelled prostacyclins [J].
Bjorkman, M ;
Andersson, Y ;
Doi, H ;
Kato, K ;
Suzuki, M ;
Noyori, R ;
Watanabe, Y ;
Langstrom, B .
ACTA CHEMICA SCANDINAVICA, 1998, 52 (05) :635-640
[3]   Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development [J].
Chiba, Masato ;
Ishii, Yasuyuki ;
Sugiyama, Yuichi .
AAPS JOURNAL, 2009, 11 (02) :262-276
[4]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[5]   Use of Tc-99m mebrofenin as a clinical probe to assess altered hepatobiliary transport:: Integration of in vitro, pharmacokinetic modeling, and simulation studies [J].
Ghibellini, Giulia ;
Leslie, Elaine M. ;
Pollack, Gary M. ;
Brouwer, Kim L. R. .
PHARMACEUTICAL RESEARCH, 2008, 25 (08) :1851-1860
[6]   Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans [J].
Hirano, M ;
Maeda, K ;
Shitara, Y ;
Sugiyama, Y .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 311 (01) :139-146
[7]   Drug-drug interaction between pitavastatin and various drugs via OATP1B1 [J].
Hirano, Masaru ;
Maeda, Kazuya ;
Shitara, Yoshihisa ;
Sugiyama, Yuichi .
DRUG METABOLISM AND DISPOSITION, 2006, 34 (07) :1229-1236
[8]   Genetic polymorphisms of uptake (OATP1B1, 1B3) and efflux (MRP2, BCRP) transporters: implications for inter-individual differences in the pharmacokinetics and pharmacodynamics of statins and other clinically relevant drugs [J].
Ieiri, Ichiro ;
Higuchi, Shun ;
Sugiyama, Yuichi .
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2009, 5 (07) :703-729
[9]   KINETIC-ANALYSIS OF INVIVO RECEPTOR-DEPENDENT BINDING OF HUMAN EPIDERMAL GROWTH-FACTOR BY RAT-TISSUES [J].
KIM, DC ;
SUGIYAMA, Y ;
SATOH, H ;
FUWA, T ;
IGA, T ;
HANANO, M .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1988, 77 (03) :200-207
[10]   Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin [J].
Kitamura, Satoshi ;
Maeda, Kazuya ;
Wang, Yi ;
Sugiyama, Yuichi .
DRUG METABOLISM AND DISPOSITION, 2008, 36 (10) :2014-2023